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analysis highlighted methodological drivers. RESULTS: CMS ini-
tially proposed four methods of computing practice expense in
2007. Three potential data sources were identiﬁed: the Socioe-
conomic Monitoring System (SMS); the Medicare Economic
Index (MEI); and the Clinical Practice Expert Panel (CPEP). The
four proposed methods utilized various combinations of these
sources. Each proposed formula was based upon a series of allo-
cations that resulted in different percentages assigned to differ-
ent subcomponents of the relevant methodology. Comparative
analysis revealed signiﬁcant differentials. Payments for drug
administration in the physician’s ofﬁce would be reduced by all
four proposed methods. Two primary methodological drivers
were identiﬁed: allocation between direct expense and indirect
expense within each formula and the volume-based allocation
method, whereby specialty impacts are recognized but are then
weighted by specialty-speciﬁc volume. CONCLUSIONS: Many
physician fee schedule payment rates in 2007, including drug
administration procedures, may be signiﬁcantly impacted by pro-
posed changes to the practice expense computation methods. It
is vital for service provider decision-makers to monitor and
understand relevant CMS proposals. Otherwise, if signiﬁcant
underpayment occurs in 2007, patient access may be negatively
affected.
PMC17
MONITORING OF PHARMACEUTICAL COST OF REIMBURSED
MEDICINES BY COMBINING OFFICIAL PHARMACY INVOICE
DATA WITH COMMERCIAL IMS SALES DATA
Van Wilder P,Arickx F,Van Haeren E, Bormans V
RIZIV-INAMI, Brussels, Belgium
OBJECTIVES: In Belgium reimbursement submissions must
contain scientiﬁc and ﬁnancial elements. The ﬁnancial part relies
on budget impact (BI) estimates from the payer’s perspective for
the next 3 years. Real cost monitoring is difﬁcult because ofﬁcial
cost data become available with a substantial delay while com-
mercial IMS data measure total sales. Our aim was to develop a
method to monitor pharmaceutical expenses in Belgium and
compare the outcome with the expected costs of the BI- estima-
tion: a method combining both data sources allowed to monitor
in a timely manner only the reimbursed pharmaceutical cost.
METHODS: The method was applied on the class of cholesterol
lowering drugs representing 9% of ambulatory expenses. BI-esti-
mations were provided in the applicant’s dossier. Monthly IMS-
sales data (=S, IMS-Health) and ofﬁcial cost data (=C, Riziv) were
extracted from the respective databases. RESULTS: All correla-
tions between historical monthly product data from both sources
yielded an R2 > 0.75 which was considered as a cut-off to apply
the method (minimal R2 = 0.8164). Expected reimbursement
pharmaceutical cost was calculated as: Expected C = S/k where
k is the average monthly ratio of S to C during a common 12
month period. The expected C calculation extends real C data by
6 months. Quality control of the method was assessed by com-
paring the expected C and real C yielding a mean monthly error
lower than 5% with a 3 month cumulated error of less than 2%.
BI-estimates were inferior to expected and real C. CONCLU-
SIONS: A method was developed to predict 3rd payer’s pharma-
ceutical cost combining recent commercial sales data and ofﬁcial
but less recent cost data ensuring reliable application of this
method for control of estimates of BI.
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OBJECTIVES: The many beneﬁts of pharmacoeconomic model-
ing using Discrete Event Simulation (DES) have increased inter-
est in this methodology. A paucity of courses applied to medical
problems however, combined with busy schedules prohibit many
professionals from familiarizing themselves with the technique.
Meeting these needs requires training that can be conducted over
the internet. METHODS: A distance learning course was devel-
oped to provide a basic understanding of DES. Using Flash tech-
nology, an internationally accepted web standard, learning
materials were organized into discrete Lessons of online infor-
mation. Each Lesson is a collection of video, narration, and text
explaining a particular aspect of DES such as its theoretical
underpinnings, examples of implemented DES solutions, and in-
depth explanations of model logic. While Lessons are grouped
together in Modules which address a speciﬁc range of concepts,
each Lesson can also stand on its own. This allows the student
to approach the course at their own pace and navigate the cur-
riculum according to personal interest and experience level. This
granular organizational method also enables individual lessons
to serve as reference materials. RESULTS: The interactive course
allows students to manipulate ﬂowchart exercises, self-certify
their knowledge through instantly processed quizzes, and contact
course administrators with questions. Accessing the course
requires only a broadband internet connection, a standard web
browser and the Flash player plug-in. CONCLUSIONS: When
considering the time and expense of attending geographically dis-
persed educational seminars, as well as the difﬁculties associated
with participating in large group lectures, the advantages of a
tailored, interactive online course become clear. Combining an
interactive multimedia presentation approach with a deep cur-
riculum and an at-your-own-pace learning process, the online
DES course provides students with an effective and convenient
solution for learning about DES in the pharmacoeconomic ﬁeld.
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OBJECTIVES: Gastrointestinal stromal tumors (GIST) is the rel-
atively new term for gastric and intestinal smooth muscle tumors
arising from mesenchymal or connective tissue. Knowledge of
the epidemiologic, health-related quality of life (HRQL), and
economic burden of GIST is important from payer, provider, 
and patient perspectives and may help guide coverage and treat-
ment decisions for treatments recently available. METHODS:
PubMed and six scientiﬁc meeting databases were searched for
studies of GIST and epidemiology, HRQL, or economics. Rele-
vant publications were assessed as to whether they provided orig-
inal empirical research. RESULTS: Eleven publications met the
review criteria: eight provided data on GIST incidence, and one
each on prevalence, HRQL, and cost. Incident cases were iden-
tiﬁed by medical record review or through extant databases with
prospective conﬁrmation by immunohistochemical staining in
six studies. The annualized incidence of GIST (cases per million)
was: United States (U.S.) (6.8), Iceland (11.0), The Netherlands
(12.7), Italy (13), Taiwan (13.7) Sweden (14.5), Finland (10–20),
and France (20.4). Prevalence was estimated at 129 cases per
million in Sweden. On the Functional Illness of Chronic
Therapy-fatigue instrument, GIST patients scored 40.0 com-
pared to 23.9, 37.6, and 43.6 in anemic cancer, non-anemic
